Topics
Sector
Geography
Subject

Videos Library

Event Videos

Medical Affairs Leaders Forum (Autumn)

October 21-22, 2015
Presentation

NICE’s Medical Technologies Evaluation Programme: A global view of a national HTA

Related topics: MedTech, Europe, UK, Market Access & HEOR
Availability: FREE
  • How applicable is MTEP outside of England?
  • How does MTEP compare to other MedTech HTA?
  • What benefit is there to submitting to MTEP?
Speaker

Joanna Entwistle
Principal Consultant, GFK Market Access, UK

Presentation

Enhancing your medical affairs communications practices

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE

How do we avoid the greatest threat to carefully crafted medical strategy – the inevitable boiling down of delicately nuanced arguments into bullet points, charts and tables? To the outside observer it appears to be largely generic and is hardly reassuring to senior stakeholders who must bless it, or clear to those who must ultimately implement it. This presentation will discuss how to create and communicate your medical strategy in a way that informs and inspires the reader.

Speaker

Robert Barker
CEO, Succinct Medical Communications, UK

Presentation

Digital medical communications: HCP demand and industry supply

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE
  • 2015 research highlights: HCP demand versus industry supply of medical content.
  • Types, sources, formats and funding of medical content: HCP behaviour and preferences.
  • Closing the gap: Overcoming challenges to meeting audience needs and increasing engagement.
  • Independent platforms: Why and how to work with them for targeted audience reach.
Speaker

Tiberio Catania
Commercial Director
EPG Health Media, UK

Presentation

Assessing the value of quantitative metrics to help identify & engage KOLs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Findings from an analysis of nearly a million data points comprising 1000 KOLs across 12 therapy areas.
  • Which quantitative metrics/characteristics correlate most closely with “KOL status”?
  • Disparity between qualitative & quantitative metrics: Does Qual add anything beyond the Quant?
  • What about identifying specific KOL subgroups? e.g. Digital KOLs,Rising stars & Orphan diseases.
  • How to apply this research to create in-house protocols for firstpass identification and validation of KOLs, easily and quickly?
Speaker

Sanjay Singhvi
Director, System Analytic, UK

 

Presentation

Disrupting conventions in medical affairs communications

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Address key medical affairs communication challenges: Case study review.
  • Disrupt traditional conventions to optimise medical strategy, hit communication objectives and maximise ROI.
  • Integrate digital technologies to gain better insight, foster more valued engagement and vitalise healthcare professional education.
  • Empower your teams to drive effective, consistent and compelling external communications.
Speakers

Chris Gray
President & Managing Director, Adelphi Communications, UK

Anne Marriott
Deputy Managing Director,
Adelphi Communications, UK

Presentation

50 Shades of real world evidence

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Dynamic mosaic of stakeholders, strategic drivers and key challenges.
  • ‘Late becomes Early’: Changing time frame of late-phase research.
  • The concept of best practices as a ‘Net Force’.
Speaker

Filip Rozewski
International Business Development
MediNeos Observational Research, Poland

Presentation

Late-phase & PASS study design considerations: Case study

Related topics: Pharmaceutical/Biotech, Europe, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Regulations & Ethics
Availability: FREE
  • When would you choose a retrospective design over a prospective design when planning for a PASS as part of a postmarketing commitment?
  • What have we seen in the PRAC feedback in the past year?
Speaker

Bettina Rillmann
Associate Director, Scientific Affairs
PRA Health Sciences, Germany

Presentation

From identification of gaps to sound prospective research: A strategic approach to medical affairs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Using existing information and prospective research in evidence generation.
  • Strategic planning and tactical decision making in RWE datageneration and utilisation.
Speaker

Xavier Fournie
Corporate Medical Director, Executive Vice-President, Global Medical Affairs – Real World Evidence, MAPI, France

Presentation

Best practice approaches in phase 4 clinical operations and implementation

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
Speaker

Alexandra Adams
Director, Late Phase, Europe
Chiltern, UK

Presentation

Evaluating critical methodological issues to optimally address the research question: What are the trade-offs among study designs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE

Research questions around real-world evidence development can include a breadth of evidence needs including the prevalence, clinical characteristics, treatment patterns and effect, etc. of a given cohort and/or sub-cohort. Addressing the question(s) can be complicated by the size/characteristics of the cohort and the complexities of the health system. Consequently, we propose a practical and feasible approach to assessing study design options which we believe will meet both the research objectives as well as consider the realities of timelines and budget constraints. We will discuss a number of options for study design and cohort identification, including use of administrative claims and/or electronic healthcare records, sitebased recruitment, and web-survey panelists. We will identify a set of common methodological challenges and discuss the relative strengths of each approach in addressing these issues.

Speaker

Teresa K Wilcox
Scientific Director, Real World Evidence, Evidera, USA